NK-1 Drug Fills Motion Sickness Gap
Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.
-
By
-
Kerri Miller
-
January 2, 2026
-
Clinical Scorecard: NK-1 Drug Fills Motion Sickness Gap
At a Glance
| Category | Detail |
|---|
| Condition | Motion Sickness |
| Key Mechanisms | Neurokinin-1 receptor antagonist targeting substance P pathway |
| Target Population | Adults experiencing motion-induced vomiting |
| Care Setting | Outpatient, during travel |
Key Highlights
- First new pharmacologic treatment for motion sickness in over 40 years
- Tradipitant significantly reduces vomiting incidence by 50% to 70%
- Favorable safety profile with common adverse reactions including somnolence and fatigue
- Not studied in pediatric patients or those with severe renal or hepatic impairment
- Ongoing development for other indications including gastroparesis
Guideline-Based Recommendations
Diagnosis
- Assess symptoms of motion sickness during travel
Management
- Prescribe tradipitant for prevention of motion-induced vomiting in adults
Monitoring & Follow-up
- Monitor for adverse reactions, especially somnolence and fatigue
Risks
- Avoid use in patients with severe renal impairment or hepatic impairment
- Caution with concomitant CNS depressants or strong CYP3A4 inhibitors
Patient & Prescribing Data
Adults with motion sickness symptoms
Tradipitant offers effective prevention without limitations of existing therapies
Clinical Best Practices
- Educate patients on potential impairment of mental and physical abilities
- Consider alternative therapies for patients with contraindications
- Monitor patients for efficacy and side effects during treatment
Related Resources & Content
